Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:alternativeName |
Veralipride
|
| gptkbp:ATCCode |
G02CB02
|
| gptkbp:CASNumber |
66644-81-3
|
| gptkbp:chemicalFormula |
C22H26N4O2S
|
| gptkbp:developedBy |
gptkb:Merck_&_Co.
|
| gptkbp:drugClass |
gptkb:benzamide_derivative
gptkb:dopamine_antagonist |
| gptkbp:marketedIn |
gptkb:France
|
| gptkbp:retired |
adverse effects
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
tardive dyskinesia
parkinsonism |
| gptkbp:usedFor |
treatment of menopausal symptoms
|
| gptkbp:withdrawn |
gptkb:France
|
| gptkbp:bfsParent |
gptkb:Aerodrom
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
MK-301
|